The FDA has given Medtronic (NYSE: MDT ) approval to use longer lengths of the company's Resolute Integrity drug-eluting stent in treating diabetes patients with coronary artery disease who have long coronary lesions, the company has announced.
This expands the applicability of the company's "marquee product."
Medtronic will now be able to use 34-mm and 38-mm lengths of the 3.0-mm, 3.5-mm, and 4.0-mm diameter stents, according to the release. These longer lengths will assist in treating long coronary lesions that span more than 27 mm, an indication that commonly emerges with individuals suffering from diabetes.
Dr. Ronald Caputo, the director of cardiac services and cardiology research at St. Joseph's Hospital in Syracuse, N.Y., was quoted in the company press release as saying, "Long coronary lesions and diabetes represent two distinct but often interrelated clinical challenges. The new sizes of the Resolute Integrity drug-eluting stent address both challenges in a single device. They have the potential to reduce procedure time and cost for clinicians and hospitals, as well as vessel trauma and contrast exposure for patients."